Browsing Tag
Oncology Trials
6 posts
Frontage Laboratories adds oncology and radiolabeled capacity to Secaucus Phase I unit for integrated CRDMO execution
Frontage Laboratories expands early-phase clinical research in U.S. and China. Find out how its oncology and AME focus could reshape sponsor strategies.
February 2, 2026
Avacta (AIM: AVCT) sets 2026 clinical momentum with AVA6103 trial launch and AVA6000 data readouts
Avacta targets dual clinical milestones in 2026 with AVA6103 trial launch and AVA6000 readouts. Find out how its small-molecule platform could reshape oncology.
January 26, 2026
Alpha Tau advances alpha DaRT with FDA approval for recurrent prostate cancer study
Find out how Alpha Tau’s FDA-approved prostate cancer trial could redefine localized salvage therapy and reshape treatment for recurrent disease.
December 2, 2025
Breakthrough trial: Oncolytics Biotech’s pelareorep combo doubles response rate in advanced anal cancer
Find out how Oncolytics Biotech’s breakthrough trial doubled response rates in advanced anal cancer and set up a 2026 FDA path.
October 28, 2025
Radiopharm Theranostics (ASX: RAD) crashes 21.6% despite A$40m capital raise and clinical milestones
Radiopharm Theranostics shares fall 21.6% after A$40m raise, but strong clinical updates and Lantheus support point to long-term upside. Read the full investor breakdown.
October 20, 2025
Akeso launches global Phase II trial of cadonilimab for IO-resistant liver cancer patients
Akeso begins a global Phase II trial of cadonilimab in advanced liver cancer. Find out how this bispecific IO drug could reshape second-line HCC therapy.
September 15, 2025